References
- SchweitzerAHornJMikolajczykRTKrauseGOttJJEstimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013Lancet2015386 1546 155510.1016/S0140-6736(15)61412-X
- TerraultNAAASLD guidelines for treatment of chronic hepatitis BHepatology20166326128310.1002/hep.28156
- BrahmaniaMFeldJArifAJanssenHLNew therapeutic agents for chronic hepatitis BLancet Infect. Dis.201616e10e2110.1016/S1473-3099(15)00436-3
- NassalMHBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis BGut2015641972198410.1136/gutjnl-2015-309809
- BaumertTFEntry of hepatitis B and C viruses - recent progress and future impactCurr. Opin. Virol.20144586510.1016/j.coviro.2013.12.002
- GlebeDMapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytesGastroenterology200512923424510.1053/j.gastro.2005.03.090
- NeurathARKentSBStrickNParkerKIdentification and chemical synthesis of a host cell receptor binding site on hepatitis B virusCell19864642943610.1016/0092-8674(86)90663-X
- GriponPCannieIUrbanSEfficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface proteinJ. Virol.2005791613162210.1128/JVI.79.3.1613-1622.2005544121
- EngelkeMCharacterization of a hepatitis B and hepatitis delta virus receptor binding siteHepatology20064375076010.1002/hep.21112
- SchulzeASchieckANiYMierWUrbanSFine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interactionJ. Virol.2010841989200010.1128/JVI.01902-09
- BlanchetMSureauCInfectivity determinants of the hepatitis B virus pre-S domain are confined to the N-terminal 75 amino acid residuesJ. Virol.2007815841584910.1128/JVI.00096-071900317
- SalisseJSureauCA function essential to viral entry underlies the hepatitis B virus “a” determinantJ. Virol.2009839321932810.1128/JVI.00678-092738268
- JaoudeGASureauCRole of the antigenic loop of the hepatitis B virus envelope proteins in infectivity of hepatitis delta virusJ. Virol.200579104601046610.1128/JVI.79.16.10460-10466.20051182656
- NeurathARStrickNSproulPSearch for hepatitis B virus cell receptors reveals binding sites for interleukin 6 on the virus envelope proteinJ. Exp. Med.199217546146910.1084/jem.175.2.461
- EisenbergCAsialoglycoprotein receptor in human isolated hepatocytes from normal liver and its apparent increase in liver with histological alterationsJ. Hepatol.19911330530910.1016/0168-8278(91)90073-K
- RyuCJAn 80-kilodalton protein that binds to the pre-S1 domain of hepatitis B virusJ. Virol.20007411011610.1128/JVI.74.1.110-116.2000111519
- GriponPHepatitis B virus infection of adult human hepatocytes cultured in the presence of dimethyl sulfoxideJ. Virol.19886241364143253845
- WalterEKeistRNiederostBPultIBlumHEHepatitis B virus infection of tupaia hepatocytes in vitro and in vivoHepatology19962415
- GriponPInfection of a human hepatoma cell line by hepatitis B virusProc. Natl. Acad. Sci. USA200299156551566010.1073/pnas.232137699
- SchulzeAGriponPUrbanSHepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycansHepatology2007461759176810.1002/hep.21896
- LeistnerCMGruen-BernhardSGlebeDRole of glycosaminoglycans for binding and infection of hepatitis B virusCell Microbiol.200810122133
- SureauCSalisseJA conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus a-determinantHepatology20135798599410.1002/hep.26125
- YanHSodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D viruseLife20121e0004910.7554/eLife.000493485615
- NiYHepatitis B and D viruses exploit sodium taurocholate cotransporting polypeptide for species-specific entry into hepatocytesGastroenterology20141461070108310.1053/j.gastro.2013.12.024
- YanHMolecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptideJ. Virol.2013877977799110.1128/JVI.03540-123700185
- KonigAKinetics of the bile acid transporter and hepatitis B virus receptor Na+/taurocholate cotransporting polypeptide (NTCP) in hepatocytesJ. Hepatol.20146186787510.1016/j.jhep.2014.05.018
- FuLHuHLiuYJingZLiWWoodchuck sodium taurocholate cotransporting polypeptide supports low-level hepatitis B and D virus entryVirology201750511110.1016/j.virol.2017.02.006
- HagenbuchBMeierPJMolecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporterJ. Clin. Invest.1994931326133110.1172/JCI117091294097
- AnwerMSStiegerBSodium-dependent bile salt transporters of the SLC10A transporter family: more than solute transportersPflug. Arch.2014466778910.1007/s00424-013-1367-0
- ZhouXStructural basis of the alternating-access mechanism in a bile acid transporterNature201450556957310.1038/nature12811
- Kullak-UblickGAStiegerBHagenbuchBMeierPJHepatic transport of bile saltsSemin. Liver Dis.20002027329210.1055/s-2000-9426
- HoRHLeakeBFRobertsRLLeeWKimRBEthnicity-dependent polymorphism in Na+-taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognitionJ. Biol. Chem.20042797213722210.1074/jbc.M305782200
- PanWGenetic polymorphisms in Na+-taurocholate cotransporting polypeptide (NTCP) and ileal apical sodium-dependent bile acid transporter (ASBT) and ethnic comparisons of functional variants of NTCP among Asian populationsXenobiotica20114150151010.3109/00498254.2011.555567
- LouXYThe effect of Na+/taurocholate cotransporting polypeptide (NTCP) c.800C>T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy malesPharmazie201469775779
- ThanapiromKAssociation of the S267F variant on NTCP gene and treatment response to pegylated interferon in patients with chronic hepatitis B: a multicentre studyAntivir. Ther.201823677510.3851/IMP3179
- YanHViral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptideJ. Virol.2014883273328410.1128/JVI.03478-133957944
- PengLThe p.Ser267Phe variant in SLC10A1 is associated with resistance to chronic hepatitis BHepatology2015611251126010.1002/hep.27608
- LiNAssociation of genetic variation of sodium taurocholate cotransporting polypeptide with chronic hepatitis B virus infectionGenet. Test Mol. Biomark.20141842542910.1089/gtmb.2013.0491
- HuHHThers2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis BGut2016651514152110.1136/gutjnl-2015-310686
- ChenXGenetic variants in the regulatory region of SLC10A1 are not associated with the risk of hepatitis B virus infection and clearanceInfect. Genet. Evol.20164449550010.1016/j.meegid.2016.07.043
- YangJA genetic variant of the NTCP gene is associated with HBV infection status in a Chinese populationBMC Cancer20161610.1186/s12885-016-2257-64788942
- SlijepcevicDImpaired uptake of conjugated bile acids and hepatitis b virus pres1-binding in na(+) -taurocholate cotransporting polypeptide knockout miceHepatology20156220721910.1002/hep.276944657468
- VazFMSodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: conjugated hypercholanemia without a clear clinical phenotypeHepatology20156126026710.1002/hep.27240
- VazFMHuidekoperHHPaulusmaCCExtended abstract: deficiency of sodium taurocholate cotransporting polypeptide (SLC10A1): a new inborn error of metabolism with an attenuated phenotypeDig. Dis.20173525926010.1159/000450984
- DengMClinical and molecular study of a pediatric patient with sodium taurocholate cotransporting polypeptide deficiencyExp. Ther. Med.2016123294330010.3892/etm.2016.37525103782
- SongYZDengM[Sodium taurocholate cotransporting polypeptide deficiency manifesting as cholestatic jaundice in early infancy: a complicated case study]Zhongguo. Dang. Dai. Er. Ke. Za. Zhi.201719350354
- LiuRHomozygous p.Ser267Phe in SLC10A1 is associated with a new type of hypercholanemia and implications for personalized medicineSci. Rep.2017710.1038/s41598-017-07012-25569087
- HagenbuchBMeierPJThe superfamily of organic anion transporting polypeptidesBiochim. Biophys. Acta2003160911810.1016/S0005-2736(02)00633-8
- BallatoriNOSTalpha-OSTbeta: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epitheliaHepatology2005421270127910.1002/hep.20961
- LevyDThe role of microsomal epoxide hydrolase, Na(+) -taurocholate cotransporting polypeptide, and organic anion transporting polypeptide in hepatic sodium-dependent bile acid transportHepatology2018671184118510.1002/hep.29712
- WagnerMZollnerGTraunerMNuclear receptor regulation of the adaptive response of bile acid transporters in cholestasisSemin. Liver Dis.20103016017710.1055/s-0030-1253225
- KeitelVExpression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasisHepatology2005411160117210.1002/hep.20682
- ElorantaJJJungDKullak-UblickGAThe human Na+-taurocholate cotransporting polypeptide gene is activated by glucocorticoid receptor and peroxisome proliferator-activated receptor-gamma coactivator-1alpha, and suppressed by bile acids via a small heterodimer partner-dependent mechanismMol. Endocrinol.200620657910.1210/me.2005-0159
- Le VeeMLecureurVStiegerBFardelORegulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6Drug Metab. Dispos.20093768569310.1124/dmd.108.023630
- BouezzedineFFardelOGriponPInterleukin 6 inhibits HBV entry through NTCP down regulationVirology2015481344210.1016/j.virol.2015.02.026
- WangLInterspecies variability in expression of hepatobiliary transporters across human, dog, monkey, and rat as determined by quantitative proteomicsDrug Metab. Dispos.20154336737410.1124/dmd.114.061580
- TsukudaSDysregulation of retinoic acid receptor diminishes hepatocyte permissiveness to hepatitis B virus infection through modulation of sodium taurocholate cotransporting polypeptide (NTCP) expressionJ. Biol. Chem.20152905673568410.1074/jbc.M114.602540
- KangJDown-regulation of NTCP expression by cyclin D1 in hepatitis B virus-related hepatocellular carcinoma has clinical significanceOncotarget201785604156050
- VerrierERSolute carrier NTCP regulates innate antiviral immune responses targeting hepatitis C virus infection of hepatocytesCell Rep.2016171357136810.1016/j.celrep.2016.09.0845098118
- RamboerEStrategies for immortalization of primary hepatocytesJ. Hepatol.20146192594310.1016/j.jhep.2014.05.046
- ZeiselMBTowards an HBV cure: state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cureGut2015641314132610.1136/gutjnl-2014-308943
- AllweissLDandriMExperimental in vitro and in vivo models for the study of human hepatitis B virus infectionJ. Hepatol.201664S17S3110.1016/j.jhep.2016.02.012
- AnderssonTBKanebrattKPKennaJGThe HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in humanExpert. Opin. Drug Metab. Toxicol.2012890992010.1517/17425255.2012.685159
- WatashiKUrbanSLiWWakitaTNTCP and beyond: opening the door to unveil hepatitis B virus entryInt. J. Mol. Sci.2014152892290510.3390/ijms150228923958888
- ThomasELiangTJExperimental models of hepatitis B and C - new insights and progressNat. Rev. Gastroenterol. Hepatol.20161336237410.1038/nrgastro.2016.375578419
- VerrierERA targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D virusesHepatology201663354810.1002/hep.28013
- ZhouMProductive HBV infection of well-differentiated, hNTCP-expressing human hepatoma-derived (Huh7) cellsVirol. Sin.20173246547510.1007/s12250-017-3983-x
- Verrier, E. R., Colpitts, C. C., Schuster, C., Zeisel, M. B. & Baumert, T. F. Cell Culture Models for the Investigation of Hepatitis B and D Virus Infection. Viruses8, pii: E261 (2016).
- SargiacomoCUpregulation of sodium taurocholate cotransporter polypeptide during hepatogenic differentiation of umbilical cord matrix mesenchymal stem cells facilitates hepatitis B entryStem Cell Res. Ther.2017820410.1186/s13287-017-0656-55622580
- Mason, W. S. Animal models and the molecular biology of hepadnavirus infection. Cold Spring Harb Perspect Med5, pii: a021352 (2015).
- WinerBYDingQGaskaJMPlossAIn vivo models of hepatitis B and C virus infectionFEBS Lett.20165901987199910.1002/1873-3468.121574945464
- SchieckAHepatitis B virus hepatotropism is mediated by specific receptor recognition in the liver and not restricted to susceptible hostsHepatology201358435310.1002/hep.26211
- DupinayTDiscovery of naturally occurring transmissible chronic hepatitis B virus infection among Macaca fascicularis from Mauritius IslandHepatology2013581610162010.1002/hep.26428
- LemppFASodium taurocholate cotransporting polypeptide is the limiting host factor of hepatitis B virus infection in macaque and pig hepatocytesHepatology20176670371610.1002/hep.29112
- BlankAFirst-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex BJ. Hepatol.20166548348910.1016/j.jhep.2016.04.013
- BlankAThe NTCP-inhibitor Myrcludex B: effects on bile acid disposition and tenofovir pharmacokineticsClin. Pharmacol. Ther.201810334134810.1002/cpt.744
- WatashiKCyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP)Hepatology2014591726173710.1002/hep.269824265264
- NkongoloSCyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptorJ. Hepatol.20146072373110.1016/j.jhep.2013.11.022
- ShimuraSCyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activityJ. Hepatol.20176668569210.1016/j.jhep.2016.11.009
- TreiberASchneiterRHauslerSStiegerBBosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafilDrug Metab. Dispos.2007351400140710.1124/dmd.106.013615
- IwamotoMEvaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCPBiochem. Biophys. Res. Commun.201444380881310.1016/j.bbrc.2013.12.052
- DongZEkinsSPolliJEQuantitative NTCP pharmacophore and lack of association between DILI and NTCP InhibitionEur. J. Pharm. Sci.2015661910.1016/j.ejps.2014.09.005
- LuciforaJEsserKProtzerUEzetimibe blocks hepatitis B virus infection after virus uptake into hepatocytesAntivir. Res.20139719519710.1016/j.antiviral.2012.12.008
- KanekoMA novel tricyclic polyketide, vanitaracin A, specifically inhibits the entry of hepatitis B and D viruses by targeting sodium taurocholate cotransporting polypeptideJ. Virol.201589119451195310.1128/JVI.01855-154645323
- HuangHC-)-Epigallocatechin-3-gallate inhibits entry of hepatitis B virus into hepatocytesAntivir. Res.201411110011110.1016/j.antiviral.2014.09.009
- DonkersJMReduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCPSci. Rep.2017710.1038/s41598-017-15338-05681660
- KoCThe FDA-approved drug irbesartan inhibits HBV-infection in HepG2 cells stably expressing sodium taurocholate cotransporting polypeptideAntivir. Ther.20152083584210.3851/IMP2965
- BlanchetMSureauCLabontePUse of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycleAntivir. Res.201410611111510.1016/j.antiviral.2014.03.017
- WangXJIrbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepatitis B virus entry by disturbing Na(+)-dependent taurocholate cotransporting polypeptide activityAntivir. Res.201512014014610.1016/j.antiviral.2015.06.007
- AhnSHGrape seed proanthocyanidin extract inhibits glutamate-induced cell death through inhibition of calcium signals and nitric oxide formation in cultured rat hippocampal neuronsBMC Neurosci.20111210.1186/1471-2202-12-783160962
- TsukudaSA new class of hepatitis B and D virus entry inhibitors, proanthocyanidin and its analogs, that directly act on the viral large surface proteinsHepatology2017651104111610.1002/hep.28952
- Li, D. et al. A potent human neutralizing antibody Fc-dependently reduces established HBV infections. Elife6, e26738 (2017).
- ChiSWBroadly neutralizing anti-hepatitis B virus antibody reveals a complementarity determining region H3 lid-opening mechanismProc. Natl. Acad. Sci. USA20071049230923510.1073/pnas.0701279104
- ZhangPYuMYVenableRAlterHJShihJWNeutralization epitope responsible for the hepatitis B virus subtype-specific protection in chimpanzeesProc. Natl. Acad. Sci. USA20061039214921910.1073/pnas.0603316103
- IshiiYSuzukiSAsaiSMuraiILiver function assessment with three (13)C breath tests by two-point measurementsIsot. Environ. Health S.20124854355710.1080/10256016.2012.682991
- ToKKWWuWKKLoongHHFPPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase inhibitors by inducing autophagyEur. J. Pharmacol.2018823192610.1016/j.ejphar.2018.01.036
- LawSWYWongAYSAnandSWongICKChanEWNeuropsychiatric events associated with leukotriene-modifying agents: a systematic reviewDrug. Saf.20184125326510.1007/s40264-017-0607-1
- AnzaiRLong-term 3,5,3’-triiodothyroacetic acid therapy in a child with hyperthyroidism caused by thyroid hormone resistance: pharmacological study and therapeutic recommendationsThyroid2012221069107510.1089/thy.2011.0450
- GoldmanPPeppercornMADrug therapy: SulfasalazineN. Engl. J. Med.1975293202310.1056/NEJM197507032930105
- YuGThe antinociceptive effects of intracerebroventricular administration of Chicago sky blue 6B, a vesicular glutamate transporter inhibitorBehav. Pharmacol.20132465365810.1097/FBP.0000000000000007